Immutep Ltd Advances Efti in Cancer Treatment Trials

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd has made significant strides in its clinical and regulatory efforts, positioning its lead candidate eftilagimod alpha (efti) for potential market approvals in Europe and the US. Notable advancements include a pivotal Phase III trial collaboration with Merck & Co for non-small cell lung cancer treatment and promising results from various trials in other cancer types. These developments highlight efti’s potential to enhance therapeutic outcomes across multiple oncology indications.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.